One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback